Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage?

Ann Clin Biochem. 2015 Jan;52(Pt 1):88-94. doi: 10.1177/0004563214528312. Epub 2014 Mar 26.


Background: It is not possible to diagnose acute kidney injury (AKI) in early stages with traditional biomarkers. Kidney injury molecule-1 (KIM-1) is a novel biomarker promising the diagnosis of AKI in early stages. We studied whether urinary and serum KIM-1 (KIM-1 U and KIM-1 S ) concentrations were useful in predicting cisplatin-induced AKI in early stages.

Methods: We prospectively analysed 22 patients on cisplatin treatment. KIM-1 S and KIM-1 U concentrations were assessed in the samples of the patients on four different time periods (before treatment [BT], first [AT1], third [AT3] and fifth [AT5] day after treatment).

Results: KIM-1 U concentrations on the first day after cisplatin treatment in patients with AKI were significantly increased compared to both KIM-1 U concentrations of the same patients BT (P=0.009) and to AT1-KIM-1 U concentrations of the patients without AKI (P=0.008). A receiver operating characteristic analysis revealed that AT1-KIM-1 U concentrations may predict AKI with an 87.5% sensitivity and 93.3% specificity (area under the curve=0.94). KIM-1 S concentrations were not significantly changed between BT and AT periods.

Conclusions: KIM-1 U concentrations may predict cisplatin-induced AKI in early stages with high sensitivity and specificity.

Keywords: Kidney injury molecule-1; acute kidney injury; biomarker; cisplatin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / blood
  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / diagnosis*
  • Acute Kidney Injury / urine*
  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Biomarkers / blood
  • Biomarkers / urine
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects*
  • Early Diagnosis
  • Female
  • Hepatitis A Virus Cellular Receptor 1
  • Humans
  • Kidney / drug effects
  • Kidney / metabolism
  • Kidney / pathology
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology
  • Male
  • Membrane Glycoproteins / blood
  • Membrane Glycoproteins / urine*
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • ROC Curve
  • Receptors, Virus / blood
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / pathology


  • Antineoplastic Agents
  • Biomarkers
  • HAVCR1 protein, human
  • Hepatitis A Virus Cellular Receptor 1
  • Membrane Glycoproteins
  • Receptors, Virus
  • Cisplatin